{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:59:09Z","timestamp":1791349149782,"version":"4.3.1"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1097\/cco.0b013e328341edff","type":"journal-article","created":{"date-parts":[[2010,12,11]],"date-time":"2010-12-11T02:29:34Z","timestamp":1292034574000},"page":"170-176","source":"Crossref","is-referenced-by-count":46,"title":["Autoimmunity and treatment outcome in melanoma"],"prefix":"10.1097","volume":"23","author":[{"given":"Marna G","family":"Bouwhuis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo LM","family":"ten Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Suciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander MM","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210128","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur J Cancer"},{"key":"R4-8-20210128","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.hoc.2009.03.009","article-title":"Melanoma and immunotherapy.","volume":"23","author":"Eggermont","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J Clin Oncol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"RESEARCH0035","DOI":"10.1186\/gb-2002-3-7-research0035","article-title":"Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration.","volume":"3","author":"Panelli","year":"2002","journal-title":"Genome Biol"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/pmic.200500004","article-title":"Inflammatory protein profile during systemic high dose interleukin-2 administration","volume":"6","author":"Rossi","year":"2006","journal-title":"Proteomics"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","article-title":"IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients","volume":"107","author":"Ahmadzadeh","year":"2006","journal-title":"Blood"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.2005.03.6830","article-title":"Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma","volume":"24","author":"Cesana","year":"2006","journal-title":"J Clin Oncol"},{"key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJM198806163182401","article-title":"Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells","volume":"318","author":"Atkins","year":"1988","journal-title":"N Engl J Med"},{"issue":"11\u201312","key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/0277-5379(90)90275-X","article-title":"Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma","volume":"26","author":"Scalzo","year":"1990","journal-title":"Eur J Cancer"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.1993.11.7.1376","article-title":"Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment","volume":"11","author":"Weijl","year":"1993","journal-title":"J Clin Oncol"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1200\/JCO.2001.19.15.3477","article-title":"Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma","volume":"19","author":"Phan","year":"2001","journal-title":"J Clin Oncol"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00002371-199511000-00008","article-title":"Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone","volume":"18","author":"Krouse","year":"1995","journal-title":"J Immunother Emphasis Tumor Immunol"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.1993.11.5.921","article-title":"Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response","volume":"11","author":"Kruit","year":"1993","journal-title":"J Clin Oncol"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1038\/sj.jid.5700545","article-title":"Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma","volume":"126","author":"Boasberg","year":"2006","journal-title":"J Invest Dermatol"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J Clin Oncol"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat Rev"},{"issue":"Suppl","key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1200\/jco.2007.25.18_suppl.8526","article-title":"Interferon alpha as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials","volume":"25","author":"Wheatley","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5 Suppl 7","key":"R25-8-20210128","first-page":"83","article-title":"Studies of interferons in the therapy of melanoma","volume":"18","author":"Kirkwood","year":"1991","journal-title":"Semin Oncol"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N Engl J Med"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/ijc.22951","article-title":"Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha","volume":"121","author":"Satzger","year":"2007","journal-title":"Int J Cancer"},{"key":"R28-8-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jnci\/djp132","article-title":"Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon","volume":"101","author":"Bouwhuis","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R29-8-20210128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S0140-6736(05)67482-X","article-title":"Postsurgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb\/III melanoma (EORTC 18952): randomised controlled trial","volume":"366","author":"Eggermont","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 5","key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S1359-6349(07)70097-6","article-title":"Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma","volume":"6","author":"Hansson","year":"2007","journal-title":"Eur J Cancer"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780400909","article-title":"Range of antinuclear antibodies in \u2018healthy\u2019 individuals","volume":"40","author":"Tan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1191\/0961203304lu521oa","article-title":"Clinical significance of antinuclear antibodies in malignant diseases: association with rheumatic and connective tissue paraneoplastic syndromes","volume":"13","author":"Solans-Laque","year":"2004","journal-title":"Lupus"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1196\/annals.1313.120","article-title":"Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural\/predictive autoantibodies","volume":"1050","author":"Shovman","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R37-8-20210128","first-page":"113","article-title":"Incidence of circulating antinuclear antibodies in cancer patients","volume":"57","author":"Imran","year":"2003","journal-title":"Indian J Med Sci"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group","volume":"68","author":"Glue","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00280-009-1072-z","article-title":"Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991)","volume":"65","author":"Eggermont","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"R40-8-20210128","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.10663","article-title":"Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation","volume":"95","author":"Bukowski","year":"2002","journal-title":"Cancer"},{"key":"R41-8-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"R42-8-20210128","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2009.24.6264","article-title":"Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies\u2013EORTC 18991","volume":"28","author":"Bouwhuis","year":"2010","journal-title":"J Clin Oncol"},{"key":"R43-8-20210128","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","article-title":"Final results of the EORTC 18871\/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg","year":"2004","journal-title":"Eur J Cancer"},{"key":"R44-8-20210128","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/jnci\/87.22.1710","article-title":"Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study","volume":"87","author":"Meyskens","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R45-8-20210128","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"R46-8-20210128","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"R48-8-20210128","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"R49-8-20210128","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R50-8-20210128","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"R51-8-20210128","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R52-8-20210128","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R53-8-20210128","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"R54-8-20210128","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"R55-8-20210128","first-page":"1048","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.","volume":"1042-","author":"Kirkwood","year":"16","journal-title":"Clin Cancer Res"},{"key":"R56-8-20210128","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21854","article-title":"Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma","volume":"106","author":"Reuben","year":"2006","journal-title":"Cancer"},{"key":"R57-8-20210128","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1038\/sj.onc.1206462","article-title":"Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity","volume":"22","author":"Ramirez-Montagut","year":"2003","journal-title":"Oncogene"},{"key":"R58-8-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0065-2776(06)90006-6","article-title":"Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo","volume":"90","author":"Uchi","year":"2006","journal-title":"Adv Immunol"},{"key":"R59-8-20210128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1034\/j.1600-065X.2002.18811.x","article-title":"Multiple pathways to tumor immunity and concomitant autoimmunity","volume":"188","author":"Turk","year":"2002","journal-title":"Immunol Rev"},{"key":"R60-8-20210128","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1084\/jem.182.5.1609","article-title":"Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein","volume":"182","author":"Hara","year":"1995","journal-title":"J Exp Med"},{"key":"R61-8-20210128","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S1074-7613(02)00327-8","article-title":"Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo","volume":"16","author":"Trcka","year":"2002","journal-title":"Immunity"},{"key":"R62-8-20210128","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1084\/jem.190.11.1717","article-title":"Coupling and uncoupling of tumor immunity and autoimmunity","volume":"190","author":"Bowne","year":"1999","journal-title":"J Exp Med"},{"key":"R63-8-20210128","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/eji.200839152","article-title":"CD4+ T-cell-mediated antitumor immunity can be uncoupled from autoimmunity via the STAT4\/STAT6 signaling axis","volume":"39","author":"Zhang","year":"2009","journal-title":"Eur J Immunol"},{"key":"R64-8-20210128","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature01621","article-title":"Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease","volume":"423","author":"Ueda","year":"2003","journal-title":"Nature"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e328341edff","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:42:53Z","timestamp":1786041773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-201103000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e328341edff","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}